Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26270721 | 0.87 | KMT2A (0.57) | ALDH1A1L3MBTL1HPGDKDM4EKMT2A | |
| SCHEMBL26270731 | 0.87 | MAPK1 (0.47) | ALDH1A1L3MBTL1HPGDKDM4EKMT2A | |
| SCHEMBL25386473 | 0.86 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1HPGDKDM4EKMT2A | |
| SCHEMBL25387527 | 0.81 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1HPGDKDM4EKMT2A | |
| SCHEMBL26270734 | 0.81 | MAPK1 (0.55) | ALDH1A1L3MBTL1HPGDKDM4EKMT2A | |
| SCHEMBL26270707 | 0.80 | MTNR1B (0.64) | ALDH1A1L3MBTL1KDM4EKMT2AMTNR1B | |
| SCHEMBL30567137 | 0.79 | POLB (0.49) | ALDH1A1L3MBTL1HPGDKDM4EKMT2A | |
| SCHEMBL25388664 | 0.79 | POLB (0.49) | ALDH1A1L3MBTL1HPGDKDM4EKMT2A | |
| SCHEMBL30567229 | 0.78 | KMT2A (0.42) | ALDH1A1L3MBTL1HPGDKDM4EKMT2A | |
| SCHEMBL26270728 | 0.78 | KMT2A (0.42) | ALDH1A1L3MBTL1HPGDKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171404-A1 | PCNA INHIBITORS AND USES THEREOF | UNITED STATES GOVERNMENT | 2025-05-29 | — | — | US | disclosed |
| EP-4490142-A2 | PCNA INHIBITORS AND USES THEREOF | City of Hope (US) | 2025-01-15 | — | — | EP | disclosed |
| WO-2023172880-A2 | PCNA INHIBITORS AND USES THEREOF | CITY OF HOPE (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172880-A2 | PCNA INHIBITORS AND USES THEREOF | CITY OF HOPE (US) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171404-A1 | PCNA INHIBITORS AND USES THEREOF | PCNA, MKI67, PCLAF | ALDH1A1 2808/4885L3MBTL1 1817/4885HPGD 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.